Boehringer Ingelheim International Gmbh

Andreas Zophel

Ingrid Maurer-Fogy

Rudolf Hauptmann

Walter Spevak

Christian Stratowa

Elinborg Ostermann

Konrad Heckl

Maria J Wiche-Castanon

Edeltraud Krystek

Horst Johann Ahorn

Birgit Jung

Christian Lillie

Karl-Heinz Heider

Peter Seither

Dieter Blaas

Hartmut Beug

Renate Konopitzky

Wolfgang Sommergruber

Timothy Skern

David R Blake

Andreas Weith

Norbert Kraut

Hans-Dieter Liebig

Ewa J Dowling

Stefan Gruenert

Ido M Tamir

Martin Jechlinger

Thomas Waerner

The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.

Antibodies to interleukin-like epithelial-mesenchymal transition inducer (ILEI)

The present invention relates to the use of pharmaceutical preparations containing manganese superoxide dismutase in a low dose for treating diseases and conditions caused by free oxygen radicals.

Use of manganese superoxide dismutase (MN-SOD) for preparing

The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.

Human manganese superoxide dismutase (hMn-SOD)

The invention relates to the expression of mature HRV proteinase 2A, the partial purification thereof and the preparation of substrates having an inhibitory effect.

Expression of mature proteinase 2A, the partial purification thereof and

Growing community of inventors

Neulengbach, Austria

Andreas Zophel